COMMUNIQUÉS West-GlobeNewswire
-
Sanofi: Information concerning the total number of voting rights and shares - August 2024
16/09/2024 - 18:44 -
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
16/09/2024 - 20:06 -
KFSHRC Redefines Global Healthcare with AI and Robotic Surgery Innovations
16/09/2024 - 21:06 -
ImmuneSensor Therapeutics to Participate in the UBS 2024 Virtual Biotechnology Private Company Symposium
16/09/2024 - 22:00 -
Galapagos receives transparency notification from EcoR1 Capital
16/09/2024 - 22:01 -
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16/09/2024 - 22:01 -
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/09/2024 - 22:01 -
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
16/09/2024 - 22:05 -
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
16/09/2024 - 22:05 -
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/09/2024 - 22:05 -
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
16/09/2024 - 22:06 -
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
16/09/2024 - 22:06 -
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
15/09/2024 - 08:37 -
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
15/09/2024 - 09:00 -
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15/09/2024 - 09:00 -
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15/09/2024 - 09:00 -
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
15/09/2024 - 12:05 -
KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions
15/09/2024 - 13:05 -
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
15/09/2024 - 14:45
Pages